scholarly journals Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yu-Heng Lai ◽  
Wei-Ning Chen ◽  
Te-Cheng Hsu ◽  
Che Lin ◽  
Yu Tsao ◽  
...  
2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20610-e20610
Author(s):  
Xiaoxia Zhu ◽  
Yu Zhang ◽  
Zhihao Zheng ◽  
Jiaxiu Luo

e20610 Background: Oligometastatic non-small cell lung cancer (NSCLC) exists high heterogeneity with distinct outcome, and there is a lack of available biomarkers for patient stratification. In this study, we identified a positron emission tomography (PET)/computed tomography(CT)-based radiomics signature capable of predicting overall survival (OS) in patients with synchronous oligometastatic NSCLC. Methods: This study consisted of 46 patients with synchronous oligometastatic NSCLC (≤5 metastases) between 2012-2018. Clinicopathologic data was acquired from medical records and database. A total of 20648 radiomic features were extracted from pretreatment CT and PET images, which were generated from the same PET/CT scanner. A radiomics signature was built by using the least absolute shrinkage and selection operator (LASSO) regression model. Multivariate Cox regression analysis was performed to establish the predictive model. The performance was evaluated with Harrell' concordance index (C-index). Results: 7 radiomics features were selected to build the radiomics signature. Multivariate analysis indicated that the radiomics signature (P = 0.007) was an independent prognostic factor, with a C-index of 0.810. Smoking status (P = 0.01) was the only independent clinicopathologic risk factor for overall survival prediction. Incorporating the radiomics signature with clinicopathologic risk factors resulted in higher performance with a C-index of 0.899. Conclusions: This study developed a radiomics model for predicting OS in synchronous oligometastatic NSCLC, which may serve as a predictive tool to identify individualized treatment strategy. Further internal and external validation of the model are required. Support: 81572279, 2016J004, LC2016PY016, 2018CR033. [Table: see text]


2019 ◽  
Author(s):  
Yu-Heng Lai ◽  
Wei-Ning Chen ◽  
Te-Cheng Hsu ◽  
Che Lin ◽  
Yu Tsao ◽  
...  

AbstractNon-small cell lung cancer (NSCLC) is one of the most common lung cancers worldwide. Accurate prognostic stratification of NSCLC can become an important clinical reference when designing therapeutic strategies for cancer patients. With this clinical application in mind, we developed a deep neural network (DNN) combining heterogeneous data sources of gene expression and clinical data to accurately predict the prognosis of NSCLC patients. Based on microarray data from a cohort set (614 patients), seven well-known NSCLC markers were used to group patients into marker- and marker+ subgroups. Using a systems biology approach, prognosis relevance values (PRV) were then calculated to select eight additional novel prognostic gene markers. Gene markers along with clinical data were then used to develop an integrative DNN via bimodal learning to predict the 5-year survival rate of NSCLC patients with tremendously high accuracy (AUC: 0.8163, accuracy: 75.44%), which is superior to all other existing methods based on AUC. Using the capability of deep learning, we believe that our predicted cancer prognosis can be a promising index helping oncologists and physicians develop personalized therapy and build the foundation of precision medicine in the future.


Sign in / Sign up

Export Citation Format

Share Document